BiotechTube
Imagine Pharma

Imagine Pharma

Philadelphia, United States· Est.
imaginepharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Imagine Pharma is a private, pre-clinical stage biotech leveraging a novel polypeptide (IMG-1) to build three distinct therapeutic platforms: Oral Delivery of biologics, novel Therapeutics, and Regenerative Medicine. Its pipeline includes early-stage programs for oral EPO, skin grafts, diabetic wounds, and autologous islet transplants for Type 1 Diabetes. The company appears to be pre-revenue, focusing on R&D and seeking partnerships to advance its broad portfolio of platform-derived programs.

AnemiaDiabetesWound HealingBurnsEndocrine Disorders

Technology Platform

Proprietary polypeptide (IMG-1) enabling three platforms: 1) Oral Delivery for biologics, 2) Therapeutics for novel drugs, and 3) Regenerative Medicine for cell culture and tissue repair.

Opportunities

The successful development of an oral delivery platform for biologics addresses a massive unmet need, potentially capturing significant market share from injectable drugs.
In regenerative medicine, a curative autologous islet therapy for Type 1 Diabetes or effective treatments for chronic wounds represent large, underserved markets with high willingness to pay.

Risk Factors

High scientific risk as the core IMG-1 platform must prove effective across multiple complex applications, especially the formidable challenge of oral biologic delivery.
The company is pre-revenue and faces significant financial risk, requiring substantial capital to advance its broad pre-clinical pipeline through costly clinical trials.

Competitive Landscape

Imagine Pharma competes in crowded and high-stakes fields. Oral biologic delivery is pursued by numerous biotechs and pharma giants. The wound care and regenerative medicine space, including diabetes cell therapy, features established players and well-funded startups, creating intense competition for funding, partnerships, and eventual market share.

More companies in Biologics / Biosimilars →More companies in United States →